Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and bi 2536

gemcitabine has been researched along with bi 2536 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bouska, J; Djuric, SW; Giranda, VL; Johnson, EF; Klinghofer, V; Lasko, LM; Luo, Y; Mitten, MJ; Penning, TD; Shoemaker, AR; Stewart, KD; Vasudevan, A; Xia, Z; Zhang, Q1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S1
Lorenz, J; Mössner, J; Thrum, S; Wiedmann, M1
Chiorean, EG; Elzey, BD; Hazbun, T; Konieczny, SF; Kuang, S; Liu, X; Liu, XS; Ratliff, TL; Rice, SJ; Song, B1

Other Studies

5 other study(ies) available for gemcitabine and bi 2536

ArticleYear
Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
    Bioorganic & medicinal chemistry letters, 2012, Dec-15, Volume: 22, Issue:24

    Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; High-Throughput Screening Assays; Humans; Mice; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Structure-Activity Relationship

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
    World journal of gastroenterology, 2010, Jan-14, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1

2010
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
    Anticancer research, 2011, Volume: 31, Issue:10

    Topics: Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Pyrroles; RNA, Messenger

2011
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histone Acetyltransferases; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Origin Recognition Complex; Pancreatic Neoplasms; Phosphorylation; Polo-Like Kinase 1; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Pteridines; Tissue Array Analysis; Xenograft Model Antitumor Assays

2013